Screener
Opus Genetics IRD Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaids and other current assets | (2,139) | (865) |
| Accounts payable | 1,155 | (718) |
| Accrued expenses | 432 | 272 |
| Net cash used in operating activities | (12,727) | (8,994) |
| Investing activities | ||
| Net cash used in investing activities | — | — |
| Financing activities | ||
| Proceeds from issuance of Series B preferred stock | 25,000 | — |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's operating cash flow?
- Opus Genetics (IRD) reported operating cash flow of -$12.73M in Q1 2026.
- How has Opus Genetics's operating cash flow changed year-over-year?
- Opus Genetics's operating cash flow decreased by 41.5% year-over-year, from -$8.99M to -$12.73M.
- What is the long-term trend for Opus Genetics's operating cash flow?
- Over 3 years (2021 to 2025), Opus Genetics's operating cash flow has grown at a 22.1% compound annual growth rate (CAGR), from -$19.37M to -$35.25M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Opus Genetics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude